Prof Fabrice André presents data at the ESMO 2018 congress in Munich from a phase III combination therapy trial including a targeted PI3K inhibitor to treat men and post-menopausal women with advanced breast cancer. For more on these findings, watch his...
Original Article: Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1